Table 1.

Clinical variables in patients treated with ICIs.

VariableGroupAll patients (n = 270)Non-HPD by RECIST (N = 241)HPD by RECIST (N = 29)P (Fisher exact test)All patientsa (N = 221)Non-HPD by TGR (N = 206)HPD by TGR (N = 14)P (Fisher exact test)
GenderFemale121 (44.8%)112 (46.5%)9 (31%)98 (44.3%)92 (44.7%)6 (42.9%)
Male149 (55.2%)129 (53.5%)20 (69%)123 (55.7%)115 (55.3%)8 (57.1%)
0.1140.908
Age (y)<65186 (68.9%)167 (69.3%)19 65.5%)149 (67.4%)142 (68.6%)7 (50%)
≥6584 (31.1%)74 (30.7%)10 (34.5%)0.67872 (32.6%)65 (31.4%)7 (50%)0.236
HistologyMelanoma55 (20.4%)50 (20.7%)5 (17.2%)42 (19%)41 (19.8%)1 (7.1%)
NSCLC32 (11.9%)28 (11.6%)4 (13.8%)27 (12.2%)26 (12.6%)1 (7.1%)
Colorectal24 (8.9%)21 (8.7%)3 (10.3%)18 (8.1%)15 (7.2%)3 (21.4%)
Gastric21 (7.8%)21 (8.7%)0 (0%)17 (7.7%)16 (7.7%)1 (7.1%)
TNBC21 (7.8%)18 (7.5%)3 (10.3%)14 (6.3%)13 (6.3%)1 (7.1%)
H&N20 (7.4%)16 (6.6%)4 (13.8%)18 (14.3%)16 (7.7%)2 (14.3%)
Cervical16 (5.9%)16 (6.6%)0 (0%)13 (6.3%)13 (6.3%)0 (0%)
Bladder14 (5.2%)11 (4.6%)3 (5.2%)10 (4.8%)10 (4.8%)1 (7.1%)
Others67 (24.8%)60 (24.0%)7 (24.1%)57 (27.5%)57 (27.5%)4 (28.6%)
0.4120.659
Lymphocyte count≤1.9205 (75.9%)182 (75.5%)23 (79.3%)167 (75.6%)155 (74.9%)12 (85.7%)
>1.965 (24.1%)59 (24.5%)6 (20.7%)54 (24.4%)52 (25.1%)2 (14.3)%)
0.6520.526
Neutrophil count≤4.9172 (63.7%)151 (62.7%)21 (72.4%)142 (62.8%)130 (62.8%)12 (85.5%
>4.998 (36.3%)90 (37.3%)8 (27.6%)79 (37.2%)77 (37.2%)2 (14.3%)
0.3020.083
dNLR≤3224 (83.3%)199 (82.9%)25 (86.2%)190 (86.4%)177 (85.9%)13 (92.9%)
>345 (16.7%)41 (17.1%)4 (13.8%)30 (13.6%)29 (14.1%)1 (7.1%)
0.7960.699
Platelet count≤300177 (65.8%)159 (66.3%)18 (62.1%)146 (66.4%)135 (65.5%)11 (78.6%)
>30092 (34.2%)81 (33.8%)11 (37.9%)74 (33.6%)71 (34.5%)3 (21.4%)
0.6540.318
Albumin<3.534 (12.6%)29 (12.1%)5 (17.2%)28 (12.7%)27 (13.1%)1 (7.1%)
≥3.5235 (87.4%)211 (87.9%)24 (82.8%)192 (87.3%)179 (86.9%)13 (92.9%)
0.3861
LDH<37572 (31.9%)62 (30.8%)10 (40%)60 (33.1%)56 (33.5%4 (28.6%)
>375154 (68.1%)139 (69.2%)15 (60%)121 (66.9%)111 (66.5%)10 (71.4%)
0.3541
No. of metastatic sites≤2141 (52.2%)130 (53.9%)11 (37.9%)122 (55.2%)118 (57%)4 (28.6%)
>2129 (47.8%)111 (46.1%)18 (62.1%)99 (44.8%)89 (43%)10 (71.4%)
0.1030.04
Liver metastasisno172 (63.7%)157 (65.1%)15 (51.7%)146 (66.1%)143 (69.1%)3 (21.4%)
yes98 (36.3%)84 (34.9%)14 (48.3%)75 (33.9%)64 (30.9%)11 (78.6%)
0.1560.001
IPI score prognosisGood103 (38.1%)91 (37.8%)12 (41.4%)92 (41.6%)88 (42.5%)4 (28.6%)
Intermediate135 (50%)120 (49.8%)15 (51.7%)107 (48.4%)98 (47.3%)9 (64.3%)
Poor32 (11.9%)30 (12.4%)2 (6.9%)22 (10%)21 (10.1%)1 (7.1%)
0.6770.470
MDA-ICI prognosisGood67 (24.8%)59 (24.5%)8 (27.6%)57 (25.8%)56 (27.1%)1 (7.1%)
Intermediate165 (61.1%)147 (61%)18 (62.1%)136 (61.5%)125 (60.4%)11 (78.6%)
Poor38 (14.1%)35 (14.5%)3 (10.3%)28 (12.7%)26 (12.6%)2 (14.3%)
0.8080.253
Previous ICI treatmentNo214 (79.6%)192 (80%)22 (75.9%)177 (80.5)165 (80.1%)12 (85.7%)
Yes55 (20.4%)48 (20%)7 (24.1%)43 (19.5%)41 (19.9%)2 (14.3%)
0.6021
Type of inhibitorPD-1174 (64.4%)151 (62.7%)23 (79.3%)140 (63.3%)130 (62.8%)10 (71.4%)
PDL196 (35.6%)90 (37.3%)6 (20.7%)81 (36.7%)77 (37.2%)4 (28.6%)
0.0770.517
Combination of ICIsNo114 (42.2%)109 (45.2%)5 (17.2%)99 (44.8%)97 (46.9%)2 (14.3%)
Yes156 (57.8%)132 (54.8%)24 (82.8%)122 (55.2%)110 (53.1%)12 (85.7%)
0.0040.018
  • aAll patients evaluable for TGR criteria.